CHO Pharma, Inc.
6586
Rank in Stocks
#12289
CHO Pharma, Inc., a biotechnology firm headquartered in Taipei City, Taiwan,... CHO Pharma, Inc., a biotechnology firm headquartered in Taipei City, Taiwan, specializes in the research and development of innovative therapeutic solutions. Central to its operations is an advanced glycoengineering platform. This proprietary technology facilitates the creation of several key therapeutic modalities, including SAR-based glycoengineered "biobetters," site-specific antibody-drug conjugates (ADCs), and novel antibodies and vaccines designed to target unique carbohydrate antigens. The company also offers CHOptimax, an innovative in vitro enzymatic single-step process. This technology allows for the precise transformation of unconjugated antibodies into either glycoengineered biobetters or ADCs. CHO Pharma boasts a robust and diverse pipeline of drug candidates spanning various therapeutic areas, all leveraging its glycoengineering expertise. Currently, several programs are in clinical development: CHO-H01 is undergoing Phase I/IIa trials for refractory non-Hodgkin lymphoma, while CHO-A04, a humanized monoclonal antibody, has entered Phase I trials targeting a range of tumor and cancer stem cells. Additionally, CHO-V08 is being developed as a vaccine against Klebsiella pneumoniae. In the preclinical stage, CHO Pharma is advancing CHO-H02, an agent designed to address various solid tumors including breast, bladder, pancreatic, ovarian, and gastric cancers. Another preclinical asset, CHO-H03, is an antibody drug being investigated for inflammatory conditions associated with autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease. Established in 2012, CHO Pharma continues to innovate from its base in Taipei City, Taiwan.
Share Price
$2.25
Last synced: 2026-11-10
Market Cap
$482.12M
Change (1 day)
-3.27%
Change (1 year)
125.96%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade CHO Pharma, Inc. (6586)
Category
Healthcare
Operating Margin for CHO Pharma, Inc. (6586)
Operating Margin as of November 2026 TTM: -17,694.31%
According to CHO Pharma, Inc.'s latest financial reports, its current operating margin (TTM) is -17,694.31%. At the end of 2025 the company had an operating margin of -22,770.16%.
Operating Margin history for CHO Pharma, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -17,694.31% | -22.29% |
| 2025 | -22,770.16% | 226.99% |
| 2024 | -6,963.49% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -584,833.33% | 9,818.97% |
| 2021 | -5,896.11% | -97.37% |
| 2020 | -224,315.94% | 80.47% |
| 2019 | -124,297.31% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -99.99% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about CHO Pharma, Inc.'s operating margin
What is CHO Pharma, Inc.'s operating margin?
CHO Pharma, Inc.'s operating margin is -17,694.31%, as of Nov 2026.
What was CHO Pharma, Inc.'s operating margin in 2025?
In 2025, CHO Pharma, Inc.'s operating margin was -22,770.16%, compared with -6,963.49% in 2024.
How has CHO Pharma, Inc.'s operating margin changed since 2020?
From 2020 to 2025, CHO Pharma, Inc.'s operating margin was highest in 2023 (0.00%) and lowest in 2022 (-584,833.33%).
How does CHO Pharma, Inc.'s operating margin compare with similar companies?
CHO Pharma, Inc.'s operating margin (-17,694.31%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.